Benjamin Tsai - Jan 3, 2023 Form 4 Insider Report for Oyster Point Pharma, Inc. (OYST)

Role
Director
Signature
/s/ Brandon Fenn, Attorney-in-Fact
Stock symbol
OYST
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/4/2023, 04:08 PM
Previous filing
Jun 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OYST Common Stock Disposition pursuant to a tender of shares in a change of control transaction -10.1K -73.8% 3.57K Jan 3, 2023 Direct F1, F2
transaction OYST Common Stock Disposed to Issuer -3.57K -100% 0 Jan 3, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OYST Stock Option (Right to Buy) Disposed to Issuer -5.36K -100% 0 Jan 3, 2023 Common Stock 5.36K $3.63 Direct F4, F5
transaction OYST Stock Option (Right to Buy) Disposed to Issuer -5.2K -100% 0 Jan 3, 2023 Common Stock 5.2K $17.74 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Benjamin Tsai is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 2)
F2 (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.
F3 This line item represents restricted stock units held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested restricted stock units was accelerated and each restricted stock unit was canceled in exchange for a cash payment equal to the Per Share Price less applicable tax withholdings.
F4 This line item represents stock options held by the Reporting Person. Upon the Merger, which constituted a "change of control" under the Issuer's Outside Director Compensation Policy, vesting of the Reporting Person's outstanding unvested stock options were accelerated, each such stock option became immediately exercisable and was canceled in exchange for a cash payment equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.
F5 Each vested option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.